<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03542669</url>
  </required_header>
  <id_info>
    <org_study_id>6B11-OCIK-I</org_study_id>
    <nct_id>NCT03542669</nct_id>
  </id_info>
  <brief_title>Study of 6b11-OCIK Injection Treatment in Patients With Recurrent Drug-resistant Ovarian Cancer</brief_title>
  <official_title>A Phase I Study of Autologous Killer Cell Injection Induced by Dendritic Dells Loaded With 6B11 Anti-idiotype Minibody (6b11 - OCIK Injection) Treatment in Patients With Recurrent Drug-resistant Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open, single-arm, phase I clinical trial to evaluate safety and efficacy and of&#xD;
      6b11-OCIK injection in the treatment of recurrent drug-resistant ovarian cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I clinical trial of cytotoxic T cell injection induced by dendritic cells&#xD;
      loaded with 6B11 anti-idiotype minibody (6b11-OCIK injection) for recurrent drug-resistant&#xD;
      ovarian cancer. Main purpose of this research is to determine the maximum tolerable dose&#xD;
      (MTD) of 6B11-OCIK injection in the treatment of patients with ovarian cancer. Moreover,&#xD;
      secondary purpose is to evaluate the effect of 6B11-OCIK injection on the immune system of&#xD;
      patients, the efficacy of autologous 6B11-OCIK injection in the treatment of patients with&#xD;
      ovarian cancer obtain and the correlation between OC166-9 antigen expression and efficacy of&#xD;
      6B11-OCIK injection. Thirdly, exploratory purpose is to evaluate the effect of 6B11-OCIK&#xD;
      injection on laboratory examination.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 3, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD</measure>
    <time_frame>1 year</time_frame>
    <description>Determine the maximum tolerable dose (MTD) of 6B11-OCIK injection in the treatment of patients with ovarian cancer base on the AE, SAE and laboratory examination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of the cell immunophenotype</measure>
    <time_frame>1 year</time_frame>
    <description>Changes in the concentrations of the cell immunophenotype (CD3+, CD3+CD4+, CD3+CD8+, CD3-CD56+, CD3-CD19+) in peripheral blood after 6B11-OCIK injection from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of the antinuclear antibody (ANA)</measure>
    <time_frame>1 year</time_frame>
    <description>Changes in the concentrations of the antinuclear antibody (ANA) in peripheral blood after 6B11-OCIK injection from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of the C-reactive protein (CRP)</measure>
    <time_frame>1 year</time_frame>
    <description>Changes in the concentrations of the C-reactive protein (CRP) in peripheral blood after 6B11-OCIK injection from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of the interleukin-6 (IL-6)</measure>
    <time_frame>1 year</time_frame>
    <description>Changes in the concentrations of the interleukin-6 (IL-6) in peripheral blood after 6B11-OCIK injection from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of the immunoglobulin</measure>
    <time_frame>1 year</time_frame>
    <description>Changes in the concentrations of the immunoglobulin in peripheral blood after 6B11-OCIK injection from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>3 years</time_frame>
    <description>Percentage of patients who achieved CR and PR after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>3 years</time_frame>
    <description>Percentage of evaluable patients who achieved CR, PR and SD after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>3 years</time_frame>
    <description>The period from the first infusion of 6B11-OCIK to first PD or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between OC166-9 antigen expression and efficacy of 6B11-OCIK injection.</measure>
    <time_frame>1 year</time_frame>
    <description>OC166-9 antigen expression and efficacy of 6B11-OCIK</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">9</enrollment>
  <condition>Recurrent Ovarian Carcinoma</condition>
  <condition>Platinum-resistant Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>6B11-OCIK injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>6B11-OCIK Injection</intervention_name>
    <description>Two infusions of 6B11-OCIK will be performed at each chemotherapy cycle (Day 3 an Day 7) during the first three cycles, while PBMC will be collected before each cycle (Day -12) during the first three cycles.</description>
    <arm_group_label>6B11-OCIK injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Subjects will be adminitered 4~6 cycles of chemotherapy (Doxorubicin, 30 mg/m^2 IV on Day 1 of every cycle)</description>
    <arm_group_label>6B11-OCIK injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. 18-70 years old patients.&#xD;
&#xD;
          2. Diagnosed as Ovarian Cancer, who had relapsed after initial treatment; Relapse after&#xD;
             drug resistance: clinical remission after early chemotherapy, but progression or&#xD;
             relapse within 6 months after chemotherapy,or achieve no response after early&#xD;
             chemotherapy.&#xD;
&#xD;
          3. Administered with Doxorubicin.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Symptomatic and uncontrolled Brain metastasis or pia meningeal metastasis; Patients&#xD;
             with spinal cord compression; Symptoms related to central nervous system lesions or&#xD;
             symptoms indicating disease progression;&#xD;
&#xD;
          2. Corticosteroid drugs (or analogues) or drugs effecting the immune system were&#xD;
             administered before infusion in 4 weeks.&#xD;
&#xD;
          3. Patients with interstitial lung disease or interstitial pneumonia, including&#xD;
             clinically significant radiation pneumonia;&#xD;
&#xD;
          4. Women with positive serum pregnancy test or lactation;&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaohong Chang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University People's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking University People's hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://doi.org/10.3389/fimmu.2021.707468</url>
    <description>Preliminary Safety and Potential Effect of 6B11-OCIK Adoptive Cell Therapy Against PlatinumResistant Recurrent or Refractory Ovarian Cancer,Frontiers in immunology,2021,12:707468</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 20, 2018</study_first_submitted>
  <study_first_submitted_qc>May 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2018</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University People's Hospital</investigator_affiliation>
    <investigator_full_name>Changxiaohong</investigator_full_name>
    <investigator_title>Director of Gynaecologic Oncology Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

